Rare, mostly benign, and increasingly treatable with acceptable neurological risk — but the words "spinal tumor" deserve real numbers, not just generic reassurance.
●Reviewed June 2026By Dr. Rodrigo Ávila CervantesSpine Neurosurgeon · FAANS · FCNS~13 min read
The essentials of this article
What is a primary spinal tumor?
How common are primary spinal tumors?
What types of primary spinal tumors exist?
Are spine tumors mostly benign or malignant?
What are the symptoms of a spinal tumor?
Hearing the words "tumor" and "spine" in the same sentence is frightening — and much of what circulates online does little to calm that fear with real information. This article answers the 11 questions patients ask most, with the real numbers behind diagnosis, surgery, and recovery.
Had spine surgery and the pain returned? Send your studies for a second opinion.
A primary spinal tumor originates directly in the structures of the spine — the bone, the meninges, the nerve roots, or the nervous tissue itself. This is different from a metastatic tumor, which arrives from a cancer that began in another organ. This article focuses specifically on primary tumors.
Primary spinal cord tumors represent between 2% and 4% of all central nervous system neoplasms, with an estimated incidence of 0.74 to 1.6 cases per 100,000 people per year.
Key fact
Within this already-rare group, intramedullary tumors (inside the spinal cord itself) represent only 20% to 30% — the tumor type most feared is also the least common.
Neyazi B et al., Dtsch Arztebl Int 2024 · ref. 4 · Surgical Neurology International, IMSCT series
They are classified according to their location relative to the spinal cord and its coverings — a distinction that determines both the surgical approach and the typical tumor behavior.
Meningiomas and nerve sheath tumors make up 60% to 70% of all primary spinal tumors. Malignant tumors represent approximately 22% of the total — a real minority, though not a negligible one.
Carlos-Escalante JA et al., World Neurosurg 2022 · ref. 1 · Noureldine MHA et al., Adv Exp Med Biol 2023 · ref. 6
Symptoms depend on the tumor's location and how fast it grows, and typically develop gradually — over weeks to months, not suddenly.
Symptoms that warrant evaluation
Progressive back or neck pain, often worse at night or when lying down
Numbness, tingling, or weakness in the arms or legs that gradually worsens
Loss of coordination or balance — difficulty walking normally
Bladder or bowel changes — urgency, retention, or incontinence
Scoliosis appearing in adulthood with no prior history of spinal curvature
Ge L et al., World Neurosurg 2019 · ref. 21
Contrast-enhanced MRI is the diagnostic standard. Contrast distinguishes tumor tissue from normal tissue and helps characterize the type of lesion by its enhancement pattern, guiding surgical planning before any incision.
Castillo M, Neuroimaging Clin N Am 1994 · ref. 17 · Shah LM, Salzman KL, Neuroimaging Clin N Am 2023 · ref. 18
Surgical resection is the main treatment, since removing the tumor is both diagnostic and therapeutic. Stereotactic radiosurgery is typically reserved for patients who are not good surgical candidates, or with recurrent or unresectable tumors.
Nordin EOR et al., Neurosurg Rev 2026 · ref. 19
This varies significantly by tumor type — and being honest about that variation matters more than giving a single reassuring average.
Gross total resection rates by tumor type
96% of hemangioblastomas, 82.5% of ependymomas, and 56% of astrocytomas achieved gross total resection in a series of 253 patients — astrocytoma is the type most likely to infiltrate without a clear surgical plane. Extramedullary tumors (schwannomas, meningiomas) have similarly high rates, generally 65–70%.
PMC12248634, series of 253 patients, 22 years · ScienceDirect, intra/extramedullary comparison
What this means for the patient
Gross total resection is the goal whenever it can be achieved safely — but "safely" takes priority over "completely." For astrocytomas, an incomplete resection that preserves neurological function is often the correct decision, not a failure.
This is the question behind all the others, and it deserves a direct answer with real numbers.
What the outcomes data actually shows
Immediately after surgery
Some degree of new or worsening neurological symptom occurs in a relevant minority of patients — a real, disclosed risk specific to intramedullary surgery, less so for extramedullary tumors.
Within the first month
In a large intramedullary tumor series, acute perioperative neurological decline improved back to baseline in nearly half of affected patients within the first month.
Long term (6–12 months onward)
Between 70% and 75% of patients have good functional outcomes, with improvement rates of 90–93% compared to their own preoperative status. A minority — between 6% and 12% depending on the series — experiences lasting decline.
The strongest predictor of a good outcome is not the tumor type — it's the patient's neurological status before surgery. This is the strongest argument against delaying evaluation: earlier surgery, on a less damaged cord, has a better prognosis.
Intraoperative neurophysiological monitoring (IONM) detects changes in spinal cord function in real time, before they become permanent. In one series using IONM in intramedullary surgery, gross total resection was achieved in all monitored cases with no progression at follow-up.
If you have progressive neurological symptoms that don't fit a common mechanical spine problem, request a contrast-enhanced MRI. Most patients with back pain don't have a tumor; but persistent or atypical symptoms deserve imaging. Early evaluation is the factor most within your control that affects the surgical outcome.
Based on the prognostic factors described in questions 8 and 9
Rare does not mean untreatable — and acting early does not mean overreacting.
Most primary tumors are benign, most can be safely resected, and most patients who enter surgery with preserved function leave functionally independent. The risk is real and worth naming — but so is the likelihood of a good outcome.
Every case at CICOVE is evaluated individually — not by protocol.
Dr. Rodrigo Ávila Cervantes
Spine Neurosurgeon · FAANS · FCNS · CICOVE Director
Hirano K, Imagama S, Sato K, et al. Primary spinal cord tumors: review of 678 surgically treated patients in Japan. A multicenter study. Eur Spine J. 2012;21(10):2019–2026.
Ahlhelm FJ, Fries P, Nabhan A, Reith W. [Spinal tumors]. Radiologe. 2010;50(2):165–178.
Momin AA, Oyem P, Patil N, et al. Epidemiology of primary malignant non-osseous spinal tumors in the United States. Spine J. 2022;22(8):1325–1333.
Orguc S, Arkun R. Primary tumors of the spine. Semin Musculoskelet Radiol. 2014;18(3):280–299.
Hachem LD, Nater A, Fehlings MG. Spinal Meningiomas. Adv Exp Med Biol. 2023;1416:69–78.
Goodwin ML, Buchowski JM, Schwab JH, Sciubba DM. Spinal Tumors: Diagnosis and Treatment. J Am Acad Orthop Surg. 2022;30(17):e1106–e1121.
Furtado AD, Panigrahy A, Fitz CR. CNS and spinal tumors. Handb Clin Neurol. 2016;136:1139–1158.
Schellinger KA, Propp JM, Villano JL, McCarthy BJ. Descriptive epidemiology of primary spinal cord tumors. J Neurooncol. 2008;87(2):173–179.
Castillo M. Contrast enhancement in primary tumors of the brain and spinal cord. Neuroimaging Clin N Am. 1994;4(1):63–80.
Shah LM, Salzman KL. Conventional and Advanced Imaging of Spinal Cord Tumors. Neuroimaging Clin N Am. 2023;33(3):389–406.
Nordin EOR, Sanker V, Heesen P, et al. Stereotactic radiosurgery (SRS) for primary intradural spinal tumors: A systematic review and meta-analysis. Neurosurg Rev. 2026;49(1):267.
Ozawa H, Aizawa T, Kanno H, Sano H, Itoi E. Epidemiology of surgically treated primary spinal cord tumors in Miyagi, Japan. Neuroepidemiology. 2013;41(3-4):156–160.
Ge L, Arul K, Mesfin A. Spinal Cord Injury From Spinal Tumors: Prevalence, Management, and Outcomes. World Neurosurg. 2019;122:e1551–e1556.
Lucas Negromonte Guerra P, Carolline Silveira da Silva I, Lima Bezerra Júnior D, Albert Primo Lopes A, de Sá Carneiro Filho G, Vieira de Carvalho Júnior E. Epidemiological and clinical characteristics of primary spinal cord glioblastomas: A systematic review and meta-analysis. J Clin Neurosci. 2024;130:110862.
Liu L, Shi L, Su Y, Wang K, Wang H. Epidemiological features of spinal intradural tumors, a single-center clinical study in Beijing, China. BMC Musculoskelet Disord. 2024;25(1):613.
Shobeiri P, Seyedmirzaei H, Kalantari A, Mohammadi E, Rezaei N, Hanaei S. The Epidemiology of Brain and Spinal Cord Tumors. Adv Exp Med Biol. 2023;1394:19–39.